StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Bristol-Myers Squibb (BMY) Part 1 of Phase 3 CheckMate -227 Trial Met Primary Endpoint
July 24, 2019 4:48 PM
Bristol-Myers Squibb Company (NYSE: BMY) announced that Part 1a of the Phase 3 CheckMate -227 trial evaluating Opdivo® (nivolumab) plus ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Corporate News
FDA
Next Articles
Bristol-Myers Squibb (BMY) Shares Decline After Part 2 of Phase 3 CheckMate -227 Did Not Meet Primary Endpoint
July 24, 2019 4:55 PM
Bristol-Myers Squibb Announces CheckMate -227 Part 1a Meets Co-Primary Endpoint of Overall Survival
July 24, 2019 4:16 PM